ONTRUZANT®

(trastuzumab-dttb) for injection,
for intravenous use 21 mg/mL

Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.

ONTRUZANT® (trastuzumab-dttb) is FDA Approved

HCPCS Code Q5112 effective July 1, 2019

US-SBF-0008708/19